Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01106586
First received: April 14, 2010
Last updated: October 9, 2015
Last verified: October 2015
Results First Received: September 20, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV
HIV Infections
Interventions: Drug: Stribild
Drug: ATV
Drug: Ritonavir
Drug: FTC/TDF
Drug: Stribild Placebo
Drug: ATV Placebo
Drug: RTV Placebo
Drug: FTC/TDF Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were enrolled at 146 sites in 16 countries. The first participant was screened on 06 April 2010. The last study visit occurred on 18 September 2014.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
1017 subjects were screened.

Reporting Groups
  Description
Stribild Stribild® (elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg) plus placebo to match atazanavir/ritonavir (ATV/r) + FTC/TDF once daily
ATV/r + FTC/TDF ATV/r 300/100 mg tablet plus FTC 200 mg/TDF 300 mg tablet plus placebo to match Stribild once daily

Participant Flow:   Overall Study
    Stribild     ATV/r + FTC/TDF  
STARTED     353     355  
COMPLETED     68     70  
NOT COMPLETED     285     285  
Adverse Event                 9                 15  
Death                 1                 3  
Pregnancy                 2                 2  
Lack of Efficacy                 1                 0  
Investigator's Discretion                 5                 8  
Withdrew Consent                 18                 30  
Lost to Follow-up                 24                 20  
Participant Noncompliance                 12                 10  
Protocol Violation                 1                 0  
Participant Transferred to Another Study                 212                 197  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug

Reporting Groups
  Description
Stribild Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) plus placebo to match ATV/r + FTC/TDF once daily
ATV/r + FTC/TDF ATV/r 300/100 mg tablet plus FTC 200 mg/TDF 300 mg tablet plus placebo to match Stribild once daily
Total Total of all reporting groups

Baseline Measures
    Stribild     ATV/r + FTC/TDF     Total  
Number of Participants  
[units: participants]
  353     355     708  
Age  
[units: years]
Mean (Standard Deviation)
  38  (10.5)     39  (9.8)     38  (10.2)  
Gender  
[units: participants]
     
Female     29     39     68  
Male     324     316     640  
Race/Ethnicity, Customized  
[units: participants]
     
American Indian or Alaska Native     2     3     5  
Asian     17     17     34  
Black or African Heritage     72     47     119  
Native Hawaiian or Pacific Islander     1     2     3  
White     250     277     527  
Other     11     9     20  
Region of Enrollment  
[units: participants]
     
Portugal     1     2     3  
United States     197     185     382  
Thailand     7     4     11  
Austria     12     8     20  
United Kingdom     11     15     26  
Switzerland     0     2     2  
Italy     9     5     14  
France     23     23     46  
Mexico     3     2     5  
Canada     19     22     41  
Belgium     9     12     21  
Australia     30     32     62  
Denmark     1     2     3  
Netherlands     2     4     6  
Germany     29     36     65  
Sweden     0     1     1  
HIV Disease Status  
[units: participants]
     
Asymptomatic     285     293     578  
Symptomatic HIV Infections     36     38     74  
AIDS     32     24     56  
Hepatitis B Virus (HBV) Infection Status  
[units: participants]
     
Negative     347     346     693  
Positive     5     7     12  
Indeterminate     0     1     1  
Not done     1     1     2  
Hepatitis C Virus (HCV) Infection Status  
[units: participants]
     
Negative     335     344     679  
Positive     18     10     28  
Indeterminate     0     0     0  
Not done     0     1     1  
HIV-1 RNA Category (copies/mL)  
[units: participants]
     
≤ 100,000 copies/mL     203     214     417  
> 100,000 copies/mL     150     141     291  
CD4 Cell Count (/µL)  
[units: participants]
     
≤ 50 μL     12     5     17  
51 to ≤ 200 μL     42     34     76  
201 to ≤ 350 μL     122     124     246  
351 to ≤ 500 μL     122     122     244  
> 500 μL     55     70     125  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48   [ Time Frame: Week 48 ]

2.  Secondary:   The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 96   [ Time Frame: Week 96 ]

3.  Secondary:   The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 144   [ Time Frame: Week 144 ]

4.  Secondary:   The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 192   [ Time Frame: Week 192 ]

5.  Secondary:   The Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 50 Copies/mL at Week 48 Using the FDA-defined Time to Loss of Virologic Response (TLOVR) Algorithm   [ Time Frame: Week 48 ]

6.  Secondary:   The Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Weeks 48, 96, 144, and 192   [ Time Frame: Baseline; Weeks 48, 96, 144, and 192 ]

7.  Secondary:   The Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48   [ Time Frame: Week 48 ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame Adverse events are reported for the double-blind treatment period of Stribild or ATV/r + Truvada up to 216 weeks plus 30 days.
Additional Description Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug

Frequency Threshold
Threshold above which other adverse events are reported   5%  

Reporting Groups
  Description
Stribild Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) plus placebo to match ATV/r + FTC/TDF once daily
ATV/r + FTC/TDF ATV/r 300/100 mg tablet plus FTC 200 mg/TDF 300 mg tablet plus placebo to match Stribild once daily

Other Adverse Events
    Stribild     ATV/r + FTC/TDF  
Total, other (not including serious) adverse events      
# participants affected / at risk     326/353 (92.35%)     326/355 (91.83%)  
Blood and lymphatic system disorders      
Lymphadenopathy † 1    
# participants affected / at risk     23/353 (6.52%)     16/355 (4.51%)  
Eye disorders      
Ocular icterus † 1    
# participants affected / at risk     2/353 (0.57%)     52/355 (14.65%)  
Gastrointestinal disorders      
Abdominal pain † 1    
# participants affected / at risk     25/353 (7.08%)     26/355 (7.32%)  
Constipation † 1    
# participants affected / at risk     20/353 (5.67%)     14/355 (3.94%)  
Diarrhoea † 1    
# participants affected / at risk     99/353 (28.05%)     121/355 (34.08%)  
Dyspepsia † 1    
# participants affected / at risk     13/353 (3.68%)     19/355 (5.35%)  
Flatulence † 1    
# participants affected / at risk     16/353 (4.53%)     32/355 (9.01%)  
Nausea † 1    
# participants affected / at risk     80/353 (22.66%)     78/355 (21.97%)  
Vomiting † 1    
# participants affected / at risk     26/353 (7.37%)     35/355 (9.86%)  
General disorders      
Fatigue † 1    
# participants affected / at risk     60/353 (17.00%)     60/355 (16.90%)  
Pyrexia † 1    
# participants affected / at risk     23/353 (6.52%)     22/355 (6.20%)  
Hepatobiliary disorders      
Jaundice † 1    
# participants affected / at risk     0/353 (0.00%)     34/355 (9.58%)  
Immune system disorders      
Seasonal allergy † 1    
# participants affected / at risk     17/353 (4.82%)     19/355 (5.35%)  
Infections and infestations      
Bronchitis † 1    
# participants affected / at risk     47/353 (13.31%)     42/355 (11.83%)  
Chlamydial infection † 1    
# participants affected / at risk     18/353 (5.10%)     17/355 (4.79%)  
Folliculitis † 1    
# participants affected / at risk     19/353 (5.38%)     22/355 (6.20%)  
Gastroenteritis † 1    
# participants affected / at risk     18/353 (5.10%)     28/355 (7.89%)  
Herpes zoster † 1    
# participants affected / at risk     15/353 (4.25%)     20/355 (5.63%)  
Influenza † 1    
# participants affected / at risk     31/353 (8.78%)     24/355 (6.76%)  
Nasopharyngitis † 1    
# participants affected / at risk     53/353 (15.01%)     57/355 (16.06%)  
Onychomycosis † 1    
# participants affected / at risk     21/353 (5.95%)     13/355 (3.66%)  
Pharyngitis † 1    
# participants affected / at risk     23/353 (6.52%)     18/355 (5.07%)  
Sinusitis † 1    
# participants affected / at risk     35/353 (9.92%)     38/355 (10.70%)  
Syphilis † 1    
# participants affected / at risk     27/353 (7.65%)     29/355 (8.17%)  
Upper respiratory tract infection † 1    
# participants affected / at risk     86/353 (24.36%)     97/355 (27.32%)  
Urinary tract infection † 1    
# participants affected / at risk     18/353 (5.10%)     20/355 (5.63%)  
Metabolism and nutrition disorders      
Decreased appetite † 1    
# participants affected / at risk     14/353 (3.97%)     19/355 (5.35%)  
Vitamin D deficiency † 1    
# participants affected / at risk     21/353 (5.95%)     19/355 (5.35%)  
Musculoskeletal and connective tissue disorders      
Arthralgia † 1    
# participants affected / at risk     35/353 (9.92%)     32/355 (9.01%)  
Back pain † 1    
# participants affected / at risk     46/353 (13.03%)     37/355 (10.42%)  
Pain in extremity † 1    
# participants affected / at risk     22/353 (6.23%)     21/355 (5.92%)  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)      
Anorectal human papilloma virus infection † 1    
# participants affected / at risk     21/353 (5.95%)     12/355 (3.38%)  
Nervous system disorders      
Dizziness † 1    
# participants affected / at risk     25/353 (7.08%)     28/355 (7.89%)  
Headache † 1    
# participants affected / at risk     67/353 (18.98%)     55/355 (15.49%)  
Paraesthesia † 1    
# participants affected / at risk     9/353 (2.55%)     21/355 (5.92%)  
Psychiatric disorders      
Anxiety † 1    
# participants affected / at risk     22/353 (6.23%)     29/355 (8.17%)  
Depression † 1    
# participants affected / at risk     47/353 (13.31%)     52/355 (14.65%)  
Insomnia † 1    
# participants affected / at risk     37/353 (10.48%)     36/355 (10.14%)  
Respiratory, thoracic and mediastinal disorders      
Cough † 1    
# participants affected / at risk     38/353 (10.76%)     46/355 (12.96%)  
Oropharyngeal pain † 1    
# participants affected / at risk     19/353 (5.38%)     32/355 (9.01%)  
Skin and subcutaneous tissue disorders      
Night sweats † 1    
# participants affected / at risk     10/353 (2.83%)     18/355 (5.07%)  
Rash † 1    
# participants affected / at risk     30/353 (8.50%)     37/355 (10.42%)  
Vascular disorders      
Hypertension † 1    
# participants affected / at risk     24/353 (6.80%)     12/355 (3.38%)  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA (17.0)



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
There were no limitations affecting the analysis or results.


  More Information